Sensus Healthcare closes $11m IPO

Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. Later that month, Sensus postponed the IPO. Last month, Sensus scaled back, saying it planned to offer 1.75 million shares at $6.25 apiece, for gross proceeds of $10.9 million. The SRT-100 system has U.S. 510(k) clearance, CE Mark approval in the European Union and approvals from the China Food &Drug Administration and Health Canada; Sensus claims more than 200 installed devices in 11 countries. The company had planned to put $3 million of the IPO proceeds toward hiring new sales reps and a director of marketing, and another $3 million into R&D for new pr...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news

Related Links:

In conclusion, miR-204-5p/TFAP2A feedback loop promoted the proliferative and motorial capacities of cervical cancer cells. This finding suggested a novel modulatory loop of miR-204-5p/TFAP2A in cervical cancer, offering promising biomarkers for cervical cancer therapy. PMID: 32474464 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both clinical/screening sets. METHODS: A total of 115 consecutive patients with CRC and matched healthy controls were included in Clinical Set. Fifty subjects with CRC, 50 subjects with advanced adenoma (AA), and 150 matched control participants free of neoplasia were included in Screening Set. RESULTS: In Clinical set, subjects with CRC presented higher levels of serum netrin-1 (513.9 ± 22.6 pg/mL) than controls (347.8 ± 20.3 pg/mL, p
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Publication date: Available online 31 May 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Jiaying Lu, Mingyue Chen, Lina Dong, Lulu Cai, Mingming Zhao, Qi Wang, Jingjing Li
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
New J. Chem., 2020, Accepted Manuscript DOI: 10.1039/D0NJ02256J, LetterPrashant Kumar, Suprakash Biswas, Apurba Lal Koner Naphthalimide-based red-emitting fluorescent read-out probes are developed for expeditious and sensitive detection of tyrosinase activity in live-cells. The probes show excellent photostability, pH-tolerance, specificity among several bio-analytes, non-toxic and extremely... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC02328K, CommunicationZhong Han, Yanjun Wang, Yuncong Chen, Hongbao Fang, Hao Yuan, Xiangchao Shi, Bai Yang, Zhongyan Chen, Weijiang He, Zijian Guo Early detection of cancer holds great promises for the control and prevention of cancer. For early detection, one of the challenges still exists in searching for methods which can illuminate... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Chem. Commun., 2020, Advance Article DOI: 10.1039/D0CC02795B, CommunicationAmelia Ultimo, Cristina de la Torre, Cristina Gim énez, Elena Aznar, Carmen Coll, M. Dolores Marcos, José R. Murguía, Ramón Martínez-Máñez, Félix Sancenón Nanoparticle –cell–nanoparticle communication by stigmergy was demonstrated using two capped nanodevices. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
CONCLUSION: Many women do not have accurate knowledge of the new NCSP. Further health promotion in this area is warranted, where the general practitioner may play a key role. SO WHAT?: While the new NCSP will lead to further reduction in cervical cancer mortality, it appears from the data that women did not fully understand cervical cancer and its screening. This suggests the need for further health education to women about updated screening guidelines. PMID: 32475013 [PubMed - as supplied by publisher]
Source: Health Promotion Journal of Australia - Category: International Medicine & Public Health Tags: Health Promot J Austr Source Type: research
Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnersh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - Category: Medical Devices Authors: Tags: Dermatology Exclusive Oncology Source Type: blogs
Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus mak...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Funding | Health | Keloids | Marketing | Medical Devices | Melanoma | Nonmelanoma Skin Cancer | Skin | Skin Cancer | Sports Medicine | Squamous Cell Carcinoma